View On Demand

The Mary Tyler Moore Foundation and the Restoring Vision Moonshot

About the Event

For more than 30 years, Mary Tyler Moore led the JDRF and the fight against Type 1 Diabetes and its complications, including Diabetic Retinal Disease (DRD), the leading cause of blindness worldwide and a disease that affected her personally.

Her husband, Dr. S. Robert Levine, is carrying on her work and helped to create the Restoring Vision Moonshot in 2018 as a special initiative of the JDRF and the Mary Tyler Moore and S. Robert Levine Charitable Foundation. The Moonshot is a global collaboration organized to provide essential research resources and deliver groundbreaking science with the overarching goal of developing methods to preserve, restore, and protect visual function in people with diabetes.

FORCE Family Office is proud to present an expert panel on this subject, including:

  • Dr. S. Robert Levine: President of the Mary Tyler Moore & S. Robert Levine, MD Charitable Foundation
  • Dr. Jennifer Sun: Chief of the Center for Clinical Eye Research and Trials of the Beetham Eye Institute, Joslin Diabetes Center, and Associate Professor of Ophthalmology at Harvard Medical School and a Co-Chair of the Restoring Vision Moonshot Steering Committee
  • Dr. Brian Levy: CEO of InflammX, a clinical stage company developing novel treatments for Diabetic Retinal Disease

They will discuss the key initiatives for the Moonshot and how they are helping support advances in research and treatment for DRD.

We hope you can join this FORCE for GOOD event by registering below. In the meantime, you can learn more about and donate to the Restoring Vision Moonshot by clicking here.

Watch On-Demand Webinar


All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.